RGBP Research | Milton Maxwell

RGBP

Regen BioPharma, Inc.

0.0084

-0.0016-16%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

463.97K

P/E (TTM)

Basic EPS (TTM)

-0.01

Dividend Yield

Recent Filings

8-K

Issued 23.7M shares, raised $192K

11/13/25Nov 13, 2025

Regen Biopharma issued 23,680,000 common shares in October-November 2025, raising $191,800 via Tier 2 Regulation A offerings and settling $43,740 in convertible debt plus interest. Sales handled directly by management, no underwriters. Capital influx bolsters cash position.

8-K

Consulting deals for HemaXellerate trial

10/3/25Oct 3, 2025

Regen Biopharma inked consulting pacts on October 2, 2025, with Dr. Harry Lander and CEO David Koos, each netting 20 million restricted common shares that vest only upon HemaXellerate's Phase I trial success. These deals lock in expertise for the stem cell therapy's safety and efficacy push in drug-refractory aplastic anemia patients, running through October 2028 or trial wrap. Shares dilute the 79.4 million outstanding pool. Forfeiture hits if the consulting ends early.

8-K

Issues 5.8M shares for $58K

9/19/25Sep 19, 2025

Regen Biopharma issued 5,820,000 common shares to unaffiliated investors on September 15-18, 2025, raising $58,200 in cash via Regulation A exemptions, with no commissions paid. Management handled direct sales. Funds bolster working capital. Dilution hits shareholders hard.

10-Q

Q3 FY2025 results

8/11/25Aug 11, 2025

Regen Biopharma held net revenue steady at $59,065 for Q3 FY2025 ended June 30, 2025, matching last year, while YTD revenue ticked up 0.001% to $177,195 from licensing deals with related parties like Zander Therapeutics. Operating loss narrowed sharply y/y to $40,756 from $107,966, thanks to zero R&D spend and a 51.2% drop in consulting fees, yet net loss widened 28.6% to $167,292, driven by a $89,259 derivative expense from convertible notes. Cash edged up to $1,761 on $224,631 in related-party borrowings, but operating cash burn eased to $223,586 from $544,247; free cash flow not disclosed in the 10-Q. Convertible notes ballooned to $769,905 amid new issuances, while equity deficit deepened to $5.8 million. FDA approval hurdles loom large for its early-stage regenerative therapies.

8-K

Regen issues discounted convertible note

8/7/25Aug 7, 2025

Regen Biopharma secured $85,000 in funding on August 5, 2025, via a $100,000 principal 6% convertible promissory note to Labrys Fund II LP, carrying a $15,000 original issue discount and maturing August 5, 2026. The note converts at 60% of the lowest trading price over the prior 20 days, potentially diluting shareholders amid the biotech's cash needs. Prepayment is restricted early on with escalating premiums up to 125%. Dilution looms large.

About

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is also developing HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.

CEO

Dr. David Raymond Koos DBA, Ph.D.

IPO

10/6/2014

Website

https://regenbiopharmainc.com

Employees

Sector

Healthcare

Industry

Biotechnology